ClinicalTrials.gg
CompletedNCT00796614Updated Oct 29, 2015Results posted

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

A Phase 2/3 interventional study of tamsulosin hydrochloride and Placebo in Bladder, Neurogenic, sponsored by Boehringer Ingelheim. Completed at 52 sites in 13 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2015-10-29.

Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
2 Years to 16 Years
Sex
All
01

Study summary

Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit

02

Conditions studied

  • Bladder, Neurogenic

Keywords

  • tamsulosin
  • pediatric
  • neurogenic bladder
03

In context

Urinary Bladder, Neurogenic

191 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.

This study's enrollment of 231 is above the median of 40 across 126 interventional studies indexed under Urinary Bladder, Neurogenic.

Browse Urinary Bladder, Neurogenic studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neuropathic bladder secondary to a known neurologic deficit (e.g. spina bifida)
  • Elevated detrusor leak point pressures (LPP) ≥40 cm H2O confirmed by two measurements

Exclusion criteria

Exclusion Criteria:

  • abnormalities as determined by the investigator
  • A history of relevant orthostatic hypotension, fainting spells or blackouts
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
231 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks

    Drug: Placebo

  • Experimental
    Low dose

    Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks

    Drug: tamsulosin hydrochloride

  • Experimental
    Medium dose

    Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks

    Drug: tamsulosin hydrochloride

  • Experimental
    High dose

    Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks

    Drug: tamsulosin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.

    The primary endpoint was response to treatment defined as patients who decreased their detrusor leak point pressure (LPP) based upon two evaluations on the same day to less than 40 cm H2O at Week 14 (end of treatment). Detrusor leak point pressure (LPP) recorded in cm H2O was obtained using a standard urodynamic technique, a cystometrogram. On treatment (OT): Consist of all on treatment data. Observations measured ≤3 days of stopping treatment was considered as on treatment. Missing data in these analyses was not replaced or imputed.

    Time frame: Week 14

Secondary outcomes

  1. Change From Baseline in LPP at Week 14 (End of Treatment)

    Change from baseline in detrusor leak point pressure (LPP) at Week 14 (end of treatment) between each dose group and the placebo group was compared for the FAS-LPP.

    Time frame: Baseline and Week 14

  2. Percentage Change From Baseline in LPP at Week 14 (End of Treatment)

    Percent changes in detrusor leak point pressure (LPP) from baseline to the end of treatment at Week 14 between each dose group and the placebo group were compared for the FAS-LPP.

    Time frame: Baseline and Week 14.

  3. Response With Regard to Hydronephrosis Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound Grading at Week 14 (End of Treatment) Compared to Baseline

    Hydronephrosis response was defined as stabilisation or improvement of hydronephrosis measured by renal ultrasound at the end of treatment when compared to baseline, based on ultrasound grading. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization

    Time frame: Baseline and Week 14

  4. Response With Regard to Hydroureter Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound at Week 14 (End of Treatment) Compared to Baseline

    Hydroureter response was defined as stabilisation or improvement based on change from baseline in the presence or absence of hydroureter at the end of treatment (Week 14). Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (Patients are classified according to the treatment they were taking at Week 14 or end of treatment) at Week 14.

    Time frame: Baseline and Week 14

  5. Change From Baseline in Urine Volume at Week 14

    Change in baseline urine volumes obtained by catheterisation as recorded in catheterisation diary at Week 14.

    Time frame: Baseline and Week 14

  6. Change From Baseline in Number of Times Patient Was Wet at Catheterisation

    Change from baseline in number of times patient was wet at time of catheterisation as recorded in catheterisation diary.

    Time frame: Baseline and Week 14

  7. Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electorocardiogram (ECG), Laboratory Values, Urinalysis, Treatment Emergent AE's and Cognitive Testing.

    Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing (blood pressure, pulse and respiratory rate), Electrocardiogram (ECG), Laboratory Values inclusive of hormonal assays, vision testing, Cognitive Testing, Occurrence of treatment emergent adverse events, Premature discontinuation of study drug due to AE and Urinalysis. Relevant findings or worsening of baseline conditions were reported as adverse events.

    Time frame: From first drug administration until 28 days after last study drug administration, upto 160 days

  8. Post Void Residual Volume at Week 14

    Median change from baseline to Week 14 in post void residual (mL) by study treatment.

    Time frame: Baseline and Week 14.

07

Results

Posted Sep 12, 2012
Limitations and caveats
Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.

Participant flow

The trial included children from 2-16 years of age, with elevated detrusor leak point pressure associated with a known neurologic defect (e.g., spina bifida). The three age strata were 2-\<5 years, 5-\<10 years and 10-16 years of age. In this study, 231 subjects were enrolled, 162 subjects were randomised and 161 subjects were treated.

Participant flow — Overall Study
MilestonePlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Started41403941
Not treated0010
Completed36363640
Not completed5431
Withdrew: Adverse event1200
Withdrew: Protocol violation0020
Withdrew: Lost to follow-up2210
Withdrew: Withdrawal by subject1001
Withdrew: Other than stated1000

Outcome measures

PrimaryResponse to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.

The primary endpoint was response to treatment defined as patients who decreased their detrusor leak point pressure (LPP) based upon two evaluations on the same day to less than 40 cm H2O at Week 14 (end of treatment). Detrusor leak point pressure (LPP) recorded in cm H2O was obtained using a standard urodynamic technique, a cystometrogram. On treatment (OT): Consist of all on treatment data. Observations measured ≤3 days of stopping treatment was considered as on treatment. Missing data in these analyses was not replaced or imputed.

Time frame:
Week 14
Reported as:
Number · Percentage of participants
Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.
Percentage of participantsPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.35.345.727.342.4
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · Regression, Logistic · p = 0.5388 · Odds ratio (or): 1.38 · 95% CI 0.50 to 3.80
  • Placebo vs Tamsulosin - Medium Dose Level · Regression, Logistic · p = 0.3430 · Odds ratio (or): 0.59 · 95% CI 0.20 to 1.76
  • Placebo vs Tamsulosin - High Dose Level · Regression, Logistic · p = 0.5209 · Odds ratio (or): 1.41 · 95% CI 0.50 to 3.97
  • Placebo vs Tamsulosin - Low Dose Level vs Tamsulosin - Medium Dose Level vs Tamsulosin - High Dose Level · Cochran-Armitage trend test · p = 0.9436
SecondaryChange From Baseline in LPP at Week 14 (End of Treatment)

Change from baseline in detrusor leak point pressure (LPP) at Week 14 (end of treatment) between each dose group and the placebo group was compared for the FAS-LPP.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · cm H2O
Change From Baseline in LPP at Week 14 (End of Treatment)
cm H2OPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Change From Baseline in LPP at Week 14 (End of Treatment)-11.4 ± 4.6-17.6 ± 4.5-4.6 ± 4.4-14.3 ± 4.3
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · ANCOVA · p = 0.3097
  • Placebo vs Tamsulosin - Medium Dose Level · ANCOVA · p = 0.2676
  • Placebo vs Tamsulosin - High Dose Level · ANCOVA · p = 0.6265
SecondaryPercentage Change From Baseline in LPP at Week 14 (End of Treatment)

Percent changes in detrusor leak point pressure (LPP) from baseline to the end of treatment at Week 14 between each dose group and the placebo group were compared for the FAS-LPP.

Time frame:
Baseline and Week 14.
Reported as:
Least squares mean · Percentage change
Percentage Change From Baseline in LPP at Week 14 (End of Treatment)
Percentage changePlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Percentage Change From Baseline in LPP at Week 14 (End of Treatment)-19.9 ± 7.3-27.4 ± 7.1-1.9 ± 7-23.9 ± 6.9
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · ANCOVA · p = 0.4359
  • Placebo vs Tamsulosin - Medium Dose Level · ANCOVA · p = 0.0658
  • Placebo vs Tamsulosin - High Dose Level · ANCOVA · p = 0.6709
SecondaryResponse With Regard to Hydronephrosis Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound Grading at Week 14 (End of Treatment) Compared to Baseline

Hydronephrosis response was defined as stabilisation or improvement of hydronephrosis measured by renal ultrasound at the end of treatment when compared to baseline, based on ultrasound grading. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization

Time frame:
Baseline and Week 14
Reported as:
Number · Participants
Response With Regard to Hydronephrosis Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound Grading at Week 14 (End of Treatment) Compared to Baseline
ParticipantsPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Left Kidney [N= 34; 34; 33; 40]32313137
Right Kidney [N= 33; 34; 34; 40]31333038
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · Regression, Logistic · p = 0.5672
  • Placebo vs Tamsulosin - Medium Dose Level · Regression, Logistic · p = 0.8724
  • Placebo vs Tamsulosin - High Dose Level · Regression, Logistic · p = 0.7674
  • Placebo vs Tamsulosin - Low Dose Level · Regression, Logistic · p = 0.5545
  • Placebo vs Tamsulosin - Medium Dose Level · Regression, Logistic · p = 0.4774
  • Placebo vs Tamsulosin - High Dose Level · Regression, Logistic · p = 0.8626
SecondaryResponse With Regard to Hydroureter Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound at Week 14 (End of Treatment) Compared to Baseline

Hydroureter response was defined as stabilisation or improvement based on change from baseline in the presence or absence of hydroureter at the end of treatment (Week 14). Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (Patients are classified according to the treatment they were taking at Week 14 or end of treatment) at Week 14.

Time frame:
Baseline and Week 14
Reported as:
Number · Participants
Response With Regard to Hydroureter Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound at Week 14 (End of Treatment) Compared to Baseline
ParticipantsPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Left Kidney (N= 34, 34, 33, 40)33333238
Right Kidney (N= 33, 34, 34, 40)33333238
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · Regression, Logistic · p = 0.9669
  • Placebo vs Tamsulosin - Medium Dose Level · Regression, Logistic · p = 0.9231
  • Placebo vs Tamsulosin - High Dose Level · Regression, Logistic · p = 0.6360
  • Placebo vs Tamsulosin - Low Dose Level · Fisher Exact · p = 1.0000
  • Placebo vs Tamsulosin - Medium Dose Level · Fisher Exact · p = 0.4925
  • Placebo vs Tamsulosin - High Dose Level · Fisher Exact · p = 0.4977
SecondaryChange From Baseline in Urine Volume at Week 14

Change in baseline urine volumes obtained by catheterisation as recorded in catheterisation diary at Week 14.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · mL
Change From Baseline in Urine Volume at Week 14
mLPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Change From Baseline in Urine Volume at Week 14-2.3 ± 14.0-32.2 ± 15.54.4 ± 16.33.3 ± 14.2
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · ANCOVA · p = 0.1373
  • Placebo vs Tamsulosin - Medium Dose Level · ANCOVA · p = 0.7440
  • Placebo vs Tamsulosin - High Dose Level · ANCOVA · p = 0.7703
SecondaryChange From Baseline in Number of Times Patient Was Wet at Catheterisation

Change from baseline in number of times patient was wet at time of catheterisation as recorded in catheterisation diary.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Times patient wet at catheterization
Change From Baseline in Number of Times Patient Was Wet at Catheterisation
Times patient wet at catheterizationPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Change From Baseline in Number of Times Patient Was Wet at Catheterisation0.3 ± 0.8-1.7 ± 0.90.0 ± 0.9-0.4 ± 0.8
Statistical analysis
  • Placebo vs Tamsulosin - Low Dose Level · ANCOVA · p = 0.0808
  • Placebo vs Tamsulosin - Medium Dose Level · ANCOVA · p = 0.8244
  • Placebo vs Tamsulosin - High Dose Level · ANCOVA · p = 0.5045
SecondaryNumber of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electorocardiogram (ECG), Laboratory Values, Urinalysis, Treatment Emergent AE's and Cognitive Testing.

Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing (blood pressure, pulse and respiratory rate), Electrocardiogram (ECG), Laboratory Values inclusive of hormonal assays, vision testing, Cognitive Testing, Occurrence of treatment emergent adverse events, Premature discontinuation of study drug due to AE and Urinalysis. Relevant findings or worsening of baseline conditions were reported as adverse events.

Time frame:
From first drug administration until 28 days after last study drug administration, upto 160 days
Reported as:
Number · Participants
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electorocardiogram (ECG), Laboratory Values, Urinalysis, Treatment Emergent AE's and Cognitive Testing.
ParticipantsPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Occurrence of treatment emergent adverse events18392415
Premature discontinuation of study drug due to AE1200
Sinus tachycardia0001
SecondaryPost Void Residual Volume at Week 14

Median change from baseline to Week 14 in post void residual (mL) by study treatment.

Time frame:
Baseline and Week 14.
Reported as:
Median · mL
Post Void Residual Volume at Week 14
mLPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Post Void Residual Volume at Week 143 ± 80.28-19 ± 66.4-1.5 ± 92.330.00 ± 58.67

Adverse events

Collected over From first drug administration until 28 days after last study drug administration, upto 160 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/41 (2.4%)13/41 (31.7%)
Tamsulosin - Low Dose Level—1/120 (0.8%)19/120 (15.8%)
Tamsulosin - Medium Dose Level—0/80 (0%)14/80 (17.5%)
Tamsulosin - High Dose Level—0/40 (0%)8/40 (20%)
Most frequent serious events
Most frequent serious events
EventPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Shunt malfunctionInjury, poisoning and procedural complications1/410/1200/800/40
HaematomaVascular disorders1/410/1200/800/40
DeathGeneral disorders0/411/1200/800/40
Most frequent other events
Most frequent other events
EventPlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose Level
Abdominal painGastrointestinal disorders6/411/1201/800/40
HeadacheNervous system disorders6/411/1203/801/40
Urinary tract infectionInfections and infestations4/418/1202/805/40
VomitingGastrointestinal disorders5/412/1204/803/40
NasopharyngitisInfections and infestations1/415/1204/804/40
ConstipationGastrointestinal disorders3/410/1200/800/40
InfluenzaInfections and infestations3/413/1201/802/40
CoughRespiratory, thoracic and mediastinal disorders0/411/1205/800/40

Baseline characteristics

Treated Set (TS): Includes all patients who were documented to have taken at least one dose of randomised treatment.

Age, Continuous
Age, Continuous(Years)PlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose LevelTotal
Mean8.4 ± 3.78.1 ± 4.28.1 ± 3.88.2 ± 4.38.2 ± 4.0
Age, Customized
Age, Customized(participants)PlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose LevelTotal
2 to < 5 years787830
5 to < 10 years1817171870
10 to 16 years1615151561
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTamsulosin - Low Dose LevelTamsulosin - Medium Dose LevelTamsulosin - High Dose LevelTotal
Female1618141664
Male2522252597
08

Study locations

52 sites
  • Los Angeles, California 90027, United States
  • Tampa, Florida 33614, United States
  • St Louis, Missouri 63110, United States
  • Buffalo, New York 14222, United States
  • Tarrytown, New York 10591, United States
  • Winston Salem, North Carolina 27157, United States
  • Akron, Ohio 44308, United States
  • Gent, 9000, Belgium
  • Santo Andre, 09060-650, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Berlin, 10115, Germany
  • Deggendorf, 94469, Germany
  • Essen, 45122, Germany
  • Hamburg, 22763, Germany
  • Mainz, 55101, Germany
  • Ahmedabad, 380-006, India
  • Belgaum, 590-010, India
  • Bengaluru, 560-010, India
  • Hyderabaad, 500-029, India
  • Kochin, 682-026, India
  • Lucknow, 226-014, India
  • Ludhiana, India
  • Manipal, 576-104, India
  • Mumbai, 400-008, India
  • Nadiad, 387-001, India
  • Nagpur, India
  • New Delhi, 110-029, India
  • Pune, 411-001, India
  • Pune, 411-053, India
  • Cagliari, 09134, Italy
  • Firenze, 50139, Italy
  • Roma, 00165, Italy
  • Gwangju, 501-757, Korea, Republic of
  • In Cheon, 400-711, Korea, Republic of
  • Pusan, 602-739, Korea, Republic of
  • Seoul, Korea, Republic of
  • Leon, 37660, Mexico
  • Puebla, 72190, Mexico
  • Manila, 1000, Philippines
  • Pasig City, 1604, Philippines
  • Quezon City, 1104, Philippines
  • Moscow, 119991, Russian Federation
  • St Petersburg, 194100, Russian Federation
  • Bloemfontein, 9300, South Africa
  • Cape Town, 7700, South Africa
  • Johannesburg, South Africa
  • Pretoria, 0028, South Africa
  • Roodepoort, South Africa
  • Barcelona, 08025, Spain
  • Madrid, 28046, Spain
  • Malaga, 29011, Spain
  • Chernivtsy, 58002, Ukraine
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2008
First posted
Nov 24, 2008
Start
Jan 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Sep 12, 2012
Last update
Oct 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00796614
Responsible party
Sponsor
First posted
Nov 24, 2008
Start date
Jan 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Sep 12, 2012
Last update
Oct 29, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion